Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

signa were given a new treatment while the others continued to receive a therapy that they had been taking for a minimum of two years(1).

During this study, discontinuation due to adverse events (AEs) occurred in 8.9% and 1% for Tasigna- and Gleevec-treated patients, respectively. The majority of these were asymptomatic laboratory adverse events. The most commonly reported AEs in the Tasigna arm were headache (36.6%), rash (23.8%) and pruritus (23.8%), while in the Gleevec arm the most commonly reported AEs were diarrhea (12.6%) and headache (9.7%)(1).

ECGs were measured at baseline (both treatment arms), at day 8 (Tasigna arm only) and at early discontinuation from study treatment (both treatment arms). No patients in the Tasigna treatment arm were reported to have QTc prolongation intervals greater than 480 msec at baseline or at day 8; four patients (4.0%) had reported QTc prolongation intervals greater than 450 msec on day 8. No patients who discontinued early had QTc prolongation intervals greater than 450 msec(1).

ENESTnd study detailsENESTnd is a Phase III randomized, open-label, multicenter trial comparing the efficacy and safety of Tasigna versus Gleevec in adult patients with newly diagnosed Ph+ CML in chronic phase. It is the largest global randomized comparison of two oral therapies ever conducted in newly diagnosed Ph+ CML patients(2).

The study is being conducted at 217 global sites with 846 patients enrolled. Patients were randomized to receive Tasigna 300 mg twice daily (n=282), Tasigna 400 mg twice daily (n=281) or Gleevec 400 mg once daily (n=283). The primary endpoint was major molecular response (MMR) at 12 months; the key secondary endpoint was durable MMR at 24 months (patients having MMR when evaluated at both 12 and 24 months). MMR was defined in this study as 0.1% or less of Bcr-Abl as measured by RQ-PCR. Planned follow-up is for five years. Patients on the Gleevec treatment arm who had suboptimal response or
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015 The ... will be a supporting organization of the Johnson ... sterilization in 2016. Johnson & Johnson ... of high-profile superbug infections in endoscopes. J&J ran ... issues between 1976 and 2003 on advances in ...
(Date:5/28/2015)... DEKALB, Ill. , May 28, 2015 ... Intent to explore an affiliation with Northwestern Memorial ... and NMHC will further define the affiliation, which ... "KishHealth is recognized for their commitment to ... Dean M. Harrison , President and Chief Executive ...
(Date:5/28/2015)... -- National Community Pharmacists Association (NCPA) CEO B. ... in response to a new report released ... number of generic drug costs increased substantially in 2013: ... expressed by NCPA and underscores the need for action ... Moreover, a 2015 survey of 700 community pharmacists concluded ...
Breaking Medicine Technology:PDA Announces Support for the Johnson & Johnson Kilmer Conference 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 2KishHealth System Explores Affiliation with Northwestern Memorial HealthCare 3NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2
... (Nasdaq: CPIX ) announced today that it ... closes on Thursday, November 11, 2010.  A conference call and ... 2010 at 5:00 p.m. Eastern Time to discuss the results. ... (for U.S. callers) or 253-237-1032 (for international callers).  A rebroadcast ...
... N.J., Oct. 28 Ten pharmacy professionals were saluted on ... event was created to honor the future of pharmacy and ... practice. Pharmacy Times and Parata partnered to recognize ... the way for the industry,s future. Mark ...
Cached Medicine Technology:Cumberland Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 11, 2010 2Next-Generation Pharmacist Winner Announced 2Next-Generation Pharmacist Winner Announced 3
(Date:5/28/2015)... (PRWEB) May 28, 2015 Dr. Paul ... surgeons , has announced that the new Houston Surgery ... American Association of Accreditation of Ambulatory Surgery Facilities awarded ... center . , According to Dr. Vitenas, the ... the standards of a Class C ambulatory surgery facility. ...
(Date:5/28/2015)... The connected car is gaining more traction ... vehicles have some iteration of a connected offering in ... insurance companies as the data collected can be used ... insurance (UBI). This is the primary reason that 800+ ... 2015 Conference & Exhibition. , Andrew Pym, TU ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Hexagon Geospatial ... (BHI) , a provider of engineering, spatial data and ... and analyze thousands of point clouds for urban change ... 2012 to 2014, the BHI Spatial Data Division implemented ... digital stereo aerial imagery. Collected by a variety of ...
(Date:5/28/2015)... 2015 lifeIMAGE announced today ... financing led by Cambia Health Solutions (Portland, ... transforming health care by creating a person-focused and economically ... network for exchanging medical imaging, will use this financing ... the breadth of its network capabilities and implement the ...
(Date:5/28/2015)... Westport, CT (PRWEB) May 28, 2015 ... mobile monitoring software, announced their partnership with ... their kids’ online activity. The partnership ... programs with WebWatcher’s comprehensive parental monitoring software ... Detective Rich Wistocki, BeSure Consulting's passion is ...
Breaking Medicine News(10 mins):Health News:Dr. Paul Vitenas’ New Houston Surgery Center Receives AAAASF Accreditation 2Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 2Health News:TU-Automotive: North America’s Leading Insurers Head to Chicago as Connected Car Motor Insurance Shifts up a Gear 3Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 2Health News:Hexagon Geospatial Supports Urban Change Detection Programs in New Mexico 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 2Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 3Health News:Cambia Health Solutions Leads New Round of Investment in lifeIMAGE 4Health News:WebWatcher Partners with BeSure Consulting 2Health News:WebWatcher Partners with BeSure Consulting 3
... Roche and Memory Pharmaceuticals (Nasdaq: MEMY ... a definitive merger agreement for Roche to acquire all ... transaction for an aggregate price of approximately USD 50 ... Memory Pharmaceuticals develops innovative drug candidates for the treatment ...
... 25 Pennsylvania will benefit a potential $16 million ... Botvin LifeSkills Training program, a drug abuse ... released by the Prevention Research Center at Pennsylvania ... of this highly effective program yields a return on ...
... DETROIT, Nov. 24 Caraco Pharmaceutical,Laboratories, Ltd. (NYSE Alternext ... response to the FDA warning letter that was received ... requested a response from Caraco,within 15 business days, ending ... As previously disclosed, the warning letter was issued ...
... , , MONDAY, Nov. 24 (HealthDay News) -- A drug ... and caused fewer side effects than the widely-used migraine ... drug maker Merck & Co. , Zolmitriptan and other ... side effects, including dizziness, tingling and numbness of the ...
... University of California, San Diego (UCSD) and the Moores ... novel drug target for an often difficult-to-treat form of ... pattern of a specific family of enzymes in patients ... of adult leukemia. , Paul Insel, M.D., professor ...
... announced on Friday that Garvan endocrinologist and PhD student, Dr ... the AAAS Science "Dance your PhD" contest. See ... Science magazine challenged researchers around the world to interpret ... share it with the world on YouTube by mid-November. ...
Cached Medicine News:Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 2Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 3Health News:Roche Signs Definitive Agreement to Acquire Memory Pharmaceuticals 4Health News:Drug Abuse and Violence Prevention Program Generates $16 Million in Potential Savings 2Health News:Drug Abuse and Violence Prevention Program Generates $16 Million in Potential Savings 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter 2Health News:New Migraine Drug Shows Promise 2Health News:UCSD researchers identify potential new drug target for chronic leukemia 2Health News:Ph.D. student Sue Lynn Lau dances her way to Chicago 2
... For Usage: ,Used primarily ... monitoring lumen is used for: ... gases especially end-tidal CO2. ... , Introducing medication. , ...
Indications For Usage: ,Jet ventilation....
Indications For Usage: , Airway management during surgical procedures. , Long-term ventilatory management. ...
Indications For Usage: , Oral Surgery. , Maxillofacial surgery. ...
Medicine Products: